QNTM

Quantum Biopharma Ltd. Subordinate Voting Shares Class B · NASDAQ

Sector Health Technology
Industry Biotechnology
Website -
Employees(FY) -
ISIN CA74764Y2050

Performance

+3.44%

-20.41%

+30.6%

-75.44%

-90.93%

YTD

-93.6%

Profile

Advanced Technical Analysis

Technical Analysis of QNTM 2024-11-22

The Moving Average Score of 70 indicates a strong bullish sentiment, while the Technical Score of 60 also reflects a positive outlook; however, the Oscillators Score of 50 suggests a neutral stance. Overall, the combined scores imply a generally bullish sentiment in the stock, with some caution advised due to the neutral oscillator reading.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of QNTM

Stock Rank

Recent News & Updates

2024-10-28 19:30
Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia(Accesswire)
2024-10-27 23:10
Christian Attar Files Market Manipulation Case On Behalf of Quantum Biopharma(Prnewswire)
2024-10-22 21:30
Freedman Normand Friedland Files Market Manipulation Case On Behalf of Quantum Biopharma(Prnewswire)
2024-10-21 19:00
Quantum Biopharma (NASDAQ:QNTM) Posts Link on Its Website to Access the Filed Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing(Yahoo Finance)
2024-10-20 23:55
Quantum BioPharma Ltd. Alleges Market Manipulation, Files Lawsuit, unbuzzed Continues To Gain Traction(Newsdirect)
2024-10-20 21:30
Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing(Newsfilecorp)
2024-10-20 19:00
Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing(Accesswire)
2024-10-14 18:00
Quantum BioPharma Ltd. (NASDAQ: QNTM): Pioneering Alcohol Metabolism Support with Unbuzzd(Newsdirect)
2024-10-06 20:40
Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South America(Newsfilecorp)
2024-09-27 08:06
Quantum Biopharma Provides Corporate Update(Accesswire)
2024-09-24 21:20
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US(Accesswire)
2024-09-13 04:00
Quantum BioPharma Closes Private Placement Offering(Newsfilecorp)
2024-09-08 19:30
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis(Accesswire)
2024-09-06 07:30
Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements(Accesswire)
2024-08-29 22:30
Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80(Yahoo Finance)
2024-08-29 19:30
Quantum Biopharma Announces Celly Nutrition Launches unbuzzd(TM) Grab-and-Go Stick Packs on Amazon.com so you can 'own NOW and what's NEXT'(Accesswire)
2024-08-23 07:30
Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update(Accesswire)
2024-08-14 18:00
FSD Pharma Completes Name Change to Quantum BioPharma and 65:1 Consolidation - Trading Under New Ticker Symbol 'QNTM'(Newsfilecorp)
2024-08-11 19:30
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday(Investorplace)
2024-08-09 04:00
FSD Pharma Announces Share Consolidation and Name Change(Newsfilecorp)
2024-08-08 22:51
FSD Pharma Is Up 216% Today. What Is Going On With HUGE Stock?(Investorplace)
2024-08-08 19:30
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development Team(Accesswire)
2024-07-24 21:20
24/7 Market News Publishes Report Covering Functional Beverage Market, Featuring FSD Pharma(Newsfilecorp)
2024-07-23 03:34
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders(Newsfilecorp)
2024-07-22 22:29
24/7 Market News Publishes Report Covering Biotech Developments, Featuring FSD Pharma(Newsfilecorp)
2024-07-03 20:00
FSD Pharma Files Amended and Restated Material Change Report(Newsfilecorp)
2024-06-28 05:00
FSD Pharma provides Corporate Update(Accesswire)
2024-06-27 19:30
FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.(Accesswire)
2024-06-26 19:30
FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia(Accesswire)
2024-06-12 19:30
FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications(Accesswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.